Sciwind Biosciences APAC CO Pty. Ltd. Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Hangzhou China (2017)

Organization Overview

First Clinical Trial
2020
NCT04389775
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Hangzhou Sciwind Biosciences Co., Ltd. | Sciwind Biosciences APAC CO Pty. Ltd. | Sciwind Biosciences USA Co., Ltd | Sciwind Biosciences USA Co., Ltd.

Active Ingredients

Drugs in Phase 3 Trials (3)

dulaglutide (trulicity) (1 trial)

metformin (glucophage) (1 trial)

xw003 (5 trials)

Drugs in Phase 2 Trials (2)

liraglutide (victoza) (1 trial)

peginterferon lambda-1a (3 trials)

Drugs in Phase 1 Trials (2)

Ecnoglutide (1 trial)

xw014 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 1)

Diabetes Mellitus, Type 2 (Phase 1)

Fatty Liver (Phase 1)

Non-alcoholic Fatty Liver Disease (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 7